KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranib
Smith, John C., Brooks, Laura, Hoff, Paulo M., McWalter, Gael, Dearden, Simon, Morgan, Shethah R., Wilson, David, Robertson, Jane D., Jürgensmeier, Juliane M.Volume:
49
Langue:
english
Journal:
European Journal of Cancer
DOI:
10.1016/j.ejca.2013.02.023
Date:
July, 2013
Fichier:
PDF, 590 KB
english, 2013
File converter
Plus de résultats de recherche
More benefits 
